A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis
Figure 5
Approximate and analytic solution of the VE model under danoprevir () or telaprevir (
) treatment with patient data.
(a,c) Approximate solution (16) compared to the analytic solution (11) for (a) danoprevir or (c) telaprevir treatment. (b,d) Different exponential terms in approximate solution compared with the exact solution, with decay phases indicated, for (b) danoprevir or (d) telaprevir treatment. Danoprevir treatment: data from patient 04-94XD (dosing 200 mg tid) in [25] with associated parameter estimates for VE model ,
,
,
,
,
, and
[unpublished]. Telaprevir treatment: data from patient 6 in [6] with associated parameter estimates
,
,
,
,
,
, and
[6].